I IMMUNOVANT INC
| Market Cap | $5.19B |
| P/E Ratio | — |
| Forward P/E | -9.90 |
| Dividend Yield | — |
| Beta | 0.63 |
| 52W Range | $12.72 - $29.25 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 30 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Venker EricChief Executive Officer | Sale | 1,409 | $24.60 | $34.66K | 02 Apr 2026 | 01 Apr 2026 |
| Venker EricChief Executive Officer | Sale | 12,820 | $24.04 | $308.19K | 02 Apr 2026 | 01 Apr 2026 |
| Van Tuyl ChristopherChief Legal Officer | Sale | 2,877 | $24.97 | $71.84K | 18 Mar 2026 | 18 Mar 2026 |
| Gloria MelanieChief Operating Officer | Sale | 942 | $28.90 | $27.22K | 25 Feb 2026 | 27 Feb 2026 |
| Gloria MelanieChief Operating Officer | Sale | 859 | $28.16 | $24.19K | 25 Feb 2026 | 27 Feb 2026 |
| Gloria MelanieChief Operating Officer | Sale | 1,437 | $26.98 | $38.77K | 25 Feb 2026 | 27 Feb 2026 |
| Stout Jay SChief Technology Officer | Sale | 1,977 | $26.03 | $51.46K | 21 Jan 2026 | 23 Jan 2026 |
| Stout Jay SChief Technology Officer | Sale | 55 | $26.92 | $1.48K | 07 Jan 2026 | 09 Jan 2026 |
| Stout Jay SChief Technology Officer | Sale | 1,148 | $26.51 | $30.43K | 07 Jan 2026 | 09 Jan 2026 |
| Van Tuyl ChristopherChief Legal Officer | Sale | 2,284 | $27.38 | $62.54K | 18 Dec 2025 | 19 Dec 2025 |
| Van Tuyl ChristopherChief Legal Officer | Sale | 8,529 | $26.78 | $228.41K | 18 Dec 2025 | 19 Dec 2025 |
| Roivant Sciences Ltd. | Buy | 16,666,666 | $21.00 | $350.00M | 12 Dec 2025 | 12 Dec 2025 |
| Fromkin Andrew J. | Sale | 2,898 | $23.95 | $69.41K | 01 Dec 2025 | 03 Dec 2025 |
| Fromkin Andrew J. | Sale | 19,351 | $23.14 | $447.78K | 01 Dec 2025 | 03 Dec 2025 |
| Hughes Douglas J. | Sale | 1,909 | $23.96 | $45.74K | 01 Dec 2025 | 03 Dec 2025 |
| Hughes Douglas J. | Sale | 13,091 | $23.14 | $302.93K | 01 Dec 2025 | 03 Dec 2025 |
| Andrew J. FromkinDirector | Sale | 2,898 | $23.95 | $69.41K | 01 Dec 2025 | 03 Dec 2025 |
| Andrew J. FromkinDirector | Sale | 19,351 | $23.14 | $447.78K | 01 Dec 2025 | 03 Dec 2025 |
| Douglas J. HughesDirector | Sale | 13,091 | $23.14 | $302.93K | 01 Dec 2025 | 03 Dec 2025 |
| Douglas J. HughesDirector | Sale | 1,909 | $23.96 | $45.74K | 01 Dec 2025 | 03 Dec 2025 |
| Gloria MelanieChief Operating Officer | Sale | 10,251 | $23.54 | $241.31K | 20 Nov 2025 | 21 Nov 2025 |
| Gloria MelanieChief Operating Officer | Sale | 2,375 | $23.97 | $56.93K | 20 Nov 2025 | 21 Nov 2025 |
| Melanie GloriaChief Operating Officer | Sale | 2,375 | $23.97 | $56.93K | 20 Nov 2025 | 21 Nov 2025 |
| Melanie GloriaChief Operating Officer | Sale | 10,251 | $23.54 | $241.31K | 20 Nov 2025 | 21 Nov 2025 |
| Stout Jay SChief Technology Officer | Sale | 2,520 | $19.03 | $47.96K | 22 Oct 2025 | 24 Oct 2025 |
| Geffner MichaelChief Medical Officer | Sale | 2,595 | $19.03 | $49.38K | 22 Oct 2025 | 24 Oct 2025 |
| Jay S StoutChief Technology Officer | Sale | 2,520 | $19.03 | $47.96K | 22 Oct 2025 | 24 Oct 2025 |
| Michael GeffnerChief Medical Officer | Sale | 2,595 | $19.03 | $49.38K | 22 Oct 2025 | 24 Oct 2025 |
| Geffner MichaelChief Medical Officer | Sale | 1,272 | $16.30 | $20.73K | 08 Oct 2025 | 10 Oct 2025 |
| Stout Jay SChief Technology Officer | Sale | 1,585 | $16.30 | $25.84K | 08 Oct 2025 | 10 Oct 2025 |
Frequently Asked Questions
What is IMVT stock price today?
IMMUNOVANT INC (IMVT) is currently trading at $25.48. The stock has a 52-week range of $12.72 to $29.25 and a market capitalization of $5.19B.
Is IMVT a good stock to buy in 2026?
IMMUNOVANT INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +26.7%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling IMVT stock?
There have been 30 insider transactions for IMVT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has IMVT stock performed over the past year?
IMMUNOVANT INC (IMVT) has returned +26.7% over the past 12 months. The stock traded between $12.72 and $29.25 during this period, and is currently at $25.48.
Which hedge funds own IMVT (IMMUNOVANT INC)?
0 tracked hedge funds currently hold IMVT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is IMVT's market cap and valuation?
IMMUNOVANT INC (IMVT) has a market capitalization of $5.19B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is IMVT's revenue and profitability?
IMMUNOVANT INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 0.63.
What sector is IMVT in and who are its biggest institutional holders?
IMMUNOVANT INC (IMVT) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.